Aft Pharms Us Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AFT PHARMS US
AFT PHARMS US has one approved drug.
There are two US patents protecting AFT PHARMS US drugs.
Drugs and US Patents for Aft Pharms Us
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aft Pharms Us | COMBOGESIC | acetaminophen; ibuprofen | TABLET;ORAL | 209471-001 | Mar 1, 2023 | RX | Yes | Yes | 11,197,830 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aft Pharms Us | COMBOGESIC | acetaminophen; ibuprofen | TABLET;ORAL | 209471-001 | Mar 1, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Aft Pharms Us | COMBOGESIC | acetaminophen; ibuprofen | TABLET;ORAL | 209471-001 | Mar 1, 2023 | RX | Yes | Yes | 11,534,407 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Aft Pharms Us
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aft Pharms Us | COMBOGESIC | acetaminophen; ibuprofen | TABLET;ORAL | 209471-001 | Mar 1, 2023 | 10,532,036 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Aft Pharms Us Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2021010338 | ⤷ Start Trial |
| Chile | 2021002252 | ⤷ Start Trial |
| Lithuania | 3930691 | ⤷ Start Trial |
| Portugal | 3930691 | ⤷ Start Trial |
| Morocco | 62176 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

